share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC ·  Jan 22 13:00

Summary by Futu AI

EyePoint Pharmaceuticals officer, DAVID S JONES, is set to sell 38,541 shares of common stock on 01/22/2024, as per the latest filing. The shares, valued at an aggregate market value of $860,235.12, were acquired on the same day through the exercise of stock options directly from the issuer. The transaction involved a cash payment made for the securities. This sale follows a period where no other securities transactions were reported by JONES in the past three months, according to the provided review of securities sold.
EyePoint Pharmaceuticals officer, DAVID S JONES, is set to sell 38,541 shares of common stock on 01/22/2024, as per the latest filing. The shares, valued at an aggregate market value of $860,235.12, were acquired on the same day through the exercise of stock options directly from the issuer. The transaction involved a cash payment made for the securities. This sale follows a period where no other securities transactions were reported by JONES in the past three months, according to the provided review of securities sold.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.